Måndag 24 November | 03:33:59 Europe / Stockholm
Svenska | English

BioStock

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Lipum’s CEO on the merger with Flerie and the path toward phase II
2025-11-20 11:38:00

Lipum is approaching clinical phase II with SOL-116, the company’s antibody-based drug candidate targeting the enzyme BSSL – a central mediator of inflammatory processes in rheumatoid arthritis (RA). After presenting new research findings that further strengthen its scientific underpinnings, Lipum and Flerie have agreed on a merger plan which – if approved on 29 December – will see Lipum become a private portfolio company within the Flerie group. BioStock spoke with CEO Ola Sandborgh for a comment.

Read the full interview at biostock.se:

Lipum's CEO on the merger with Flerie and the path towards phase II
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter 
Follow BioStock on social media: LinkedIn and Facebook!  
 
About BioStock 
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden